Biotech Distilled

Substack ↗ Subscribe

Subscribe Substack ↗ About

Research Areas Modalities Phases Targets Catalysts Filings Track record Movers The Lead Compound

Home › Targets › NaV1.1

NaV1.1 (1 companies · 1 programs)

Companies with an active program directed at NaV1.1.

Stoke Therapeutics, Inc. STOK

zorevunersen — Dravet Syndrome Phase 3

Track record About Feedback Report a bug Substack ↗

This website is an encyclopedia of clinical-stage biotech companies, refreshed weekly. For informational and educational use only — not investment advice. Always verify against primary sources before making decisions.